Developer docs
API playgroundTry for free, no card

Search company profiles

Lincoln Pharmaceuticals Ltd., India

Full company profile

uuid002g16m

Namestring
Lincoln Pharmaceuticals Ltd., India
Legal namestring
Lincoln Pharmaceuticals Ltd.
Company typeenum
Public
Founded yearint
1979
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAhmedabad, India
HQ citystring
Ahmedabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulations, generic medicines, drug delivery systems, anti-infective therapeutics, pharmaceutical manufacturing
Industry6 codes
1OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
CodeCRADAMACPrimaryYes
2Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
CodeHLAIAAAEPrimaryNo
3Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
CodeCRADAMADPrimaryNo
4Dermatology & Aesthetics Pharmaceuticals
CodeHLAIAAAKPrimaryNo
5Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
CodeHLAIAAAJPrimaryNo
6Compounding Ingredient & API Distributors (Pharma Supply)
CodeHLAIAJAOPrimaryNo
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Formulations
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Formulations Sales
TypeOne Time License
Description

Manufacturing and sale of pharmaceutical formulations including tablets, capsules, injectables, syrups, and ointments. Revenue generated through domestic distribution network and international exports to 60+ countries.

lincolnpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 11 records shown
1Luther Aqua
Description

Pharmaceutical formulation brand

lincolnpharma.com
+10 more records
Core offering1 text field

Lincoln Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations including tablets, capsules, injectables, syrups, and ointments across 15 therapeutic areas such as anti-infective, respiratory, gynecology, cardio & CNS, anti-diabetic, and anti-malaria. The company has developed 600+ formulations and 1,700+ registered products, with proprietary novel drug delivery systems (NDDS), Transdermal Absorption Enhancer (TAE) technology, and PROGLET bilayer tablet technology. Products are sold domestically across 26 Indian states and exported to 60+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Consistent profit growth for 10+ consecutive years - one of only 16 Indian companies to achieve this
+1 more record
Product overview1 text field

Lincoln Pharmaceuticals is a pharmaceutical company offering a diverse portfolio of 600+ formulations across 15 therapeutic areas with over 1,700 registered products and 700 in pipeline. The company operates as a unified product portfolio with multiple dosage forms (Tablets, Capsules, Injectables, Syrups, Ointments) and branded products. Key differentiated offerings include innovative drug delivery systems like PA-12 with PROGLET bilayer technology for pain management, Diclofenac Gel portfolio with TAE technology for topical pain relief, and Domi Up (Ondansetron Oral Spray) as a novel NDDS formulation. The company maintains strong presence in anti-infective, respiratory, gynecology, cardio & CNS, anti-diabetic, and anti-malaria therapeutic segments. Products are distributed domestically across 26 states in India through 50,000+ retailers and exported to 60+ countries globally.

Product and service10 records
1Diclofenac Gel Portfolio
CategoryTopical Pain Management
Description

Topical NSAID gel portfolio featuring proprietary Transdermal Absorption Enhancer (TAE) technology for localized pain relief with minimized systemic exposure. Sold to distributors, pharmacies, and healthcare providers for patient use.

2PA-12 (PARALIB) Bilayer Tablet
CategoryAnalgesic Tablet
Description

Bilayer paracetamol 1000mg tablet combining immediate-release and sustained-release layers for pain and fever management across chronic conditions (osteoarthritis, lower back pain) and acute conditions (fever, dental pain, injuries).

3Domi Up (Ondansetron Oral Spray)
CategoryAntiemetic
Description

NDDS (Novel Drug Delivery System) oral spray formulation of Ondansetron for nausea and vomiting management, delivering faster onset of action compared to conventional tablet formulations.

4Vaginal Spray
CategoryGynecology
Description

Patented intravaginal delivery spray product for women's health applications.

5Vitamin C + Zinc Tablets
CategoryNutritional Supplement
Description

Vitamin C and Zinc supplement tablets for immunity and nutritional support.

6Anti-infective Formulations
CategoryAnti-infective Therapeutics
Description

Antibiotic and antimicrobial pharmaceutical formulations for treating infectious diseases across domestic and international markets.

7Anti-malaria Formulations
CategoryAnti-malaria Therapeutics
Description

Patented antimalarial drug formulations developed and commercialized for malaria treatment across endemic markets.

8Respiratory System Products
CategoryRespiratory Therapeutics
Description

Pharmaceutical formulations for respiratory conditions including cough, cold, asthma, and bronchial disorders sold under brands like Nam Cold DX and Nam Cold Z.

9Cardio & CNS Products
CategoryCardio & CNS Therapeutics
Description

Cardiovascular and central nervous system pharmaceutical formulations including high-value chronic disease treatments.

10Anti-diabetic Products
CategoryAnti-diabetic Therapeutics
Description

Pharmaceutical formulations for diabetes management across the chronic disease segment.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeOthers
Description

Environmental NGO focused on sustainable development and environmental conservation in Gujarat through afforestation, watershed management, and water-scarce community support.

Strategic tierMinorTypeOthers
Description

Grassroots NGO dedicated to sustainable development and environmental conservation, collaborating on tree plantation drives, lake desilting projects, and water conservation initiatives.

3Vicharta Samuday Samarthan Manch (VSSM)
Strategic tierMinorTypeOthers
Description

NGO focused on supporting drought-prone and rural communities with innovative conservation practices to restore natural resources and promote climate resilience.

lincolnpharma.com
Strategic tierMinorTypeOthers
Description

Premier music institution in Ahmedabad dedicated to preserving and promoting Indian classical music through education and annual festival. Lincoln Pharma sponsors music education programs and the annual festival.

Strategic tierMinorTypeOthers
Description

National NGO providing education, healthcare, and livelihood support to underprivileged children and families. Lincoln Pharma backs child education programs and skill-building workshops.

Strategic tierMinorTypeOthers
Description

NGO focusing on child welfare, education, and youth engagement through grassroots initiatives. Supports educational access and youth skill development programs.

7Bharat Ke Veer
Strategic tierMinorTypeOthers
Description

Government-backed initiative allowing citizens to contribute to families of martyred soldiers. Lincoln Pharma provides financial assistance to martyr families.

lincolnpharma.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-cap Indian formulations manufacturer with similar India + emerging-markets export mix, multi-therapeutic portfolio, and branded generics strategy. Closely comparable on size, regulatory footprint, and product breadth.

TypeBroad incumbent
Description

Larger Indian pharma with broader international footprint and R&D scale than Lincoln, but overlapping therapeutic segments (dermatology, respiratory, cardiac) and similar branded-generic positioning.

TypeDirect peer
Description

Indian formulations and API manufacturer with parallel focus on oncology, anti-viral, and chronic segments; comparable on the mix of domestic brand-led generics and international expansion posture.

TypeDirect peer
Description

Indian formulations manufacturer with comparable API + finished-dose business, US FDA and EU-GMP approved plants, and overlap in dermatology, anti-infective, and cardiac segments.

TypeDirect peer
Description

Indian mid-cap pharma with strong domestic field force, OTC and prescription portfolio, and exports across emerging markets—highly comparable on distribution model and therapeutic mix to Lincoln.

TypeDirect peer
Description

Indian formulations manufacturer with API operations and exports to regulated and emerging markets, overlapping in cardiovascular, anti-infective, and pain management categories.

TypeBroad incumbent
Description

Larger Indian pharma with strong domestic field force model mirroring Lincoln's 600+ field force approach, plus emerging-markets exports, with overlap in chronic care and cardiovascular segments.

TypeDirect peer
Description

Indian pharma manufacturer with significant emerging-markets exports and regulated-market focus, including Africa. Comparable on geographic targeting and oral solid dosage portfolio.

TypeDirect peer
Description

Integrated Indian pharma combining API manufacturing with finished formulations across anti-malarial, anti-infective, and chronic care—directly comparable to Lincoln's API + formulations model and target markets.

TypeDirect peer
Description

Indian pharma manufacturer with India domestic + global export model, including women's health, derma, and cardiovascular—therapeutic categories directly overlapping Lincoln's portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lincoln Pharmaceuticals Ltd., India

Pharmaceutical Formulationslincolnpharma.com

Lincoln Pharmaceuticals Ltd., India firmographics

Firmographics
Name
Lincoln Pharmaceuticals Ltd., India
Legal name
Lincoln Pharmaceuticals Ltd.
Website
https://lincolnpharma.com
Company type
Public
Founded year
1979
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Lincoln Pharmaceuticals Ltd., India industry classification

Industry
Product category
Pharmaceutical Formulations
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)
akta.pro secondary industries
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

  • Pharmaceutical formulations
  • Generic medicines
  • Drug delivery systems
  • Anti-infective therapeutics
  • Pharmaceutical manufacturing

Where Lincoln Pharmaceuticals Ltd., India is headquartered

Location

Headquarters

HQ city
Ahmedabad
HQ country
India
HQ region
Asia

Offices4 records

Markets served

Lincoln Pharmaceuticals Ltd., India business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Pharmaceutical Formulations Sales: Manufacturing and sale of pharmaceutical formulations including tablets, capsules, injectables, syrups, and ointments. Revenue generated through domestic distribution network and international exports to 60+ countries.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Lincoln Pharmaceuticals Ltd., India product offering

Product offering

Core offering

Lincoln Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations including tablets, capsules, injectables, syrups, and ointments across 15 therapeutic areas such as anti-infective, respiratory, gynecology, cardio & CNS, anti-diabetic, and anti-malaria. The company has developed 600+ formulations and 1,700+ registered products, with proprietary novel drug delivery systems (NDDS), Transdermal Absorption Enhancer (TAE) technology, and PROGLET bilayer tablet technology. Products are sold domestically across 26 Indian states and exported to 60+ countries.

Product overview

Lincoln Pharmaceuticals is a pharmaceutical company offering a diverse portfolio of 600+ formulations across 15 therapeutic areas with over 1,700 registered products and 700 in pipeline. The company operates as a unified product portfolio with multiple dosage forms (Tablets, Capsules, Injectables, Syrups, Ointments) and branded products. Key differentiated offerings include innovative drug delivery systems like PA-12 with PROGLET bilayer technology for pain management, Diclofenac Gel portfolio with TAE technology for topical pain relief, and Domi Up (Ondansetron Oral Spray) as a novel NDDS formulation. The company maintains strong presence in anti-infective, respiratory, gynecology, cardio & CNS, anti-diabetic, and anti-malaria therapeutic segments. Products are distributed domestically across 26 states in India through 50,000+ retailers and exported to 60+ countries globally.

Differentiator

Problem solved

Functional benefit

Brands

  • Luther Aqua: Pharmaceutical formulation brand
  • Nam Cold DX
  • Vivian Gel
  • PA-12 (PARALIB)
  • Prolin
  • Nam Cold Z
  • Ryno
  • Charge-Up
  • Domi-Up (Ondansetron Oral Spray)
  • Emmufast
  • RELAXO/VIVIAN/DIKON/DIFLAME/DORGEL/DICLOGEL/DIKON PLUS/DICLIQUE/ALVIOL/DIPHADIC

Products and services

  • Diclofenac Gel Portfolio Topical NSAID gel portfolio featuring proprietary Transdermal Absorption Enhancer (TAE) technology for localized pain relief with minimized systemic exposure. Sold to distributors, pharmacies, and healthcare providers for patient use.
  • PA-12 (PARALIB) Bilayer Tablet Bilayer paracetamol 1000mg tablet combining immediate-release and sustained-release layers for pain and fever management across chronic conditions (osteoarthritis, lower back pain) and acute conditions (fever, dental pain, injuries).
  • Domi Up (Ondansetron Oral Spray) NDDS (Novel Drug Delivery System) oral spray formulation of Ondansetron for nausea and vomiting management, delivering faster onset of action compared to conventional tablet formulations.
  • Vaginal Spray Patented intravaginal delivery spray product for women's health applications.
  • Vitamin C + Zinc Tablets Vitamin C and Zinc supplement tablets for immunity and nutritional support.
  • Anti-infective Formulations Antibiotic and antimicrobial pharmaceutical formulations for treating infectious diseases across domestic and international markets.
  • Anti-malaria Formulations Patented antimalarial drug formulations developed and commercialized for malaria treatment across endemic markets.
  • Respiratory System Products Pharmaceutical formulations for respiratory conditions including cough, cold, asthma, and bronchial disorders sold under brands like Nam Cold DX and Nam Cold Z.
  • Cardio & CNS Products Cardiovascular and central nervous system pharmaceutical formulations including high-value chronic disease treatments.
  • Anti-diabetic Products Pharmaceutical formulations for diabetes management across the chronic disease segment.

Quantifiable outcome

  • Consistent profit growth for 10+ consecutive years - one of only 16 Indian companies to achieve this
  • +1 more outcomes

Companies that use Lincoln Pharmaceuticals Ltd., India

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Lincoln Pharmaceuticals Ltd., India technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Lincoln Pharmaceuticals Ltd., India partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor.

  • Green Leaf TrustminorOthersEnvironmental NGO focused on sustainable development and environmental conservation in Gujarat through afforestation, watershed management, and water-scarce community support.
  • Setu TrustminorOthersGrassroots NGO dedicated to sustainable development and environmental conservation, collaborating on tree plantation drives, lake desilting projects, and water conservation initiatives.
  • Vicharta Samuday Samarthan Manch (VSSM)minorOthersNGO focused on supporting drought-prone and rural communities with innovative conservation practices to restore natural resources and promote climate resilience.
  • Saptak School of MusicminorOthersPremier music institution in Ahmedabad dedicated to preserving and promoting Indian classical music through education and annual festival. Lincoln Pharma sponsors music education programs and the annual festival.
  • Smile FoundationminorOthersNational NGO providing education, healthcare, and livelihood support to underprivileged children and families. Lincoln Pharma backs child education programs and skill-building workshops.
  • AASMAAN FoundationminorOthersNGO focusing on child welfare, education, and youth engagement through grassroots initiatives. Supports educational access and youth skill development programs.
  • Bharat Ke VeerminorOthersGovernment-backed initiative allowing citizens to contribute to families of martyred soldiers. Lincoln Pharma provides financial assistance to martyr families.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Lincoln Pharmaceuticals Ltd., India competitors and assessment

Company assessment

Direct peers

  • Ajanta Pharma: Mid-cap Indian formulations manufacturer with similar India + emerging-markets export mix, multi-therapeutic portfolio, and branded generics strategy. Closely comparable on size, regulatory footprint, and product breadth.
  • Natco Pharma: Indian formulations and API manufacturer with parallel focus on oncology, anti-viral, and chronic segments; comparable on the mix of domestic brand-led generics and international expansion posture.
  • Alembic Pharmaceuticals: Indian formulations manufacturer with comparable API + finished-dose business, US FDA and EU-GMP approved plants, and overlap in dermatology, anti-infective, and cardiac segments.
  • J B Chemicals & Pharmaceuticals: Indian mid-cap pharma with strong domestic field force, OTC and prescription portfolio, and exports across emerging markets—highly comparable on distribution model and therapeutic mix to Lincoln.
  • Unichem Laboratories: Indian formulations manufacturer with API operations and exports to regulated and emerging markets, overlapping in cardiovascular, anti-infective, and pain management categories.
  • Strides Pharma: Indian pharma manufacturer with significant emerging-markets exports and regulated-market focus, including Africa. Comparable on geographic targeting and oral solid dosage portfolio.
  • IPCA Laboratories: Integrated Indian pharma combining API manufacturing with finished formulations across anti-malarial, anti-infective, and chronic care—directly comparable to Lincoln's API + formulations model and target markets.
  • Emcure Pharmaceuticals: Indian pharma manufacturer with India domestic + global export model, including women's health, derma, and cardiovascular—therapeutic categories directly overlapping Lincoln's portfolio.

Broad incumbents

  • Glenmark Pharmaceuticals: Larger Indian pharma with broader international footprint and R&D scale than Lincoln, but overlapping therapeutic segments (dermatology, respiratory, cardiac) and similar branded-generic positioning.
  • Torrent Pharmaceuticals: Larger Indian pharma with strong domestic field force model mirroring Lincoln's 600+ field force approach, plus emerging-markets exports, with overlap in chronic care and cardiovascular segments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lincoln Pharmaceuticals Ltd., India social profiles

Digital presence

Lincoln Pharmaceuticals Ltd., India compliance and trust

Trust signal

Compliance5 records

Lincoln Pharmaceuticals Ltd., India financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lincoln Pharmaceuticals Ltd., India leadership team

Management profile

Number of profiles

Profiles3 records

Lincoln Pharmaceuticals Ltd., India subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Lincoln Pharmaceuticals Ltd., India funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lincoln Pharmaceuticals Ltd., India M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lincoln Pharmaceuticals Ltd., India

What does Lincoln Pharmaceuticals Ltd., India do?

Lincoln Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations including tablets, capsules, injectables, syrups, and ointments across 15 therapeutic areas such as anti-infective, respiratory, gynecology, cardio & CNS, anti-diabetic, and anti-malaria. The company has developed 600+ formulations and 1,700+ registered products, with proprietary novel drug delivery systems (NDDS), Transdermal Absorption Enhancer (TAE) technology, and PROGLET bilayer tablet technology. Products are sold domestically across 26 Indian states and exported to 60+ countries.

Is Lincoln Pharmaceuticals Ltd., India a public or private company?

Lincoln Pharmaceuticals Ltd., India is a public company. It is classified as public and is currently operating.

When was Lincoln Pharmaceuticals Ltd., India founded?

Lincoln Pharmaceuticals Ltd., India was founded in 1979. It employs 51 to 100 people.

Where is Lincoln Pharmaceuticals Ltd., India based?

Lincoln Pharmaceuticals Ltd., India is headquartered in Ahmedabad, India, in the Asia region.

How does Lincoln Pharmaceuticals Ltd., India make money?

One revenue line is on record: pharmaceutical Formulations Sales.

Who are Lincoln Pharmaceuticals Ltd., India's main competitors?

Direct peers on record are Ajanta Pharma, Natco Pharma, Alembic Pharmaceuticals, J B Chemicals & Pharmaceuticals, Unichem Laboratories, Strides Pharma, IPCA Laboratories and Emcure Pharmaceuticals. Broad incumbents are Glenmark Pharmaceuticals and Torrent Pharmaceuticals.

Does Lincoln Pharmaceuticals Ltd., India have an API?

No public API is recorded for Lincoln Pharmaceuticals Ltd., India.

What industry is Lincoln Pharmaceuticals Ltd., India in?

Lincoln Pharmaceuticals Ltd., India's product category is Pharmaceutical Formulations. Its primary akta.pro industry code is CRADAMAC, OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXLincoln Pharmaceuticals appoints Pradeep Yadav as SGM Quality AssuranceLincoln Pharmaceuticals appointed Pradeep Kumar Yadav as Senior General Manager, Quality Assurance, effective September 24, 2026, and accepted Manoj Rai's resignation from the same role. Yadav brings over 20 years of pharmaceutical experience, including managing USFDA, MHRA, TGA, and WHO Geneva inspections. The appointment is disclosed under SEBI LODR regulations.ScanXLincoln Pharmaceuticals proposes ₹1.80 per share final dividend for FY26Lincoln Pharmaceuticals proposed a final dividend of ₹1.80 per share for FY26, an 18% payout on the ₹10 face value. The 32nd AGM is scheduled for September 30, 2026, with a record date of September 11, 2026. The meeting will be held via video conferencing.The TribuneAngel One recommends Buy on Lincoln Pharmaceuticals Ltd with a Target Price of Rs. 845 per share, potential upside 39%Angel One recommends a Buy on Lincoln Pharmaceuticals with a target price of Rs 845, citing Q1 FY27 net profit of Rs 36.23 crore, up 30.90% year-on-year. The stock trades at 14.5x trailing earnings, below the sector median of 30x, and the company targets Rs 1,000 crore revenue over three years.ScanXLincoln Pharma sets September 11 record date for 32nd AGMLincoln Pharmaceuticals announced on August 29, 2026 that its 32nd Annual General Meeting will be held on September 30, 2026 via video conferencing, with the record date set for September 11, 2026. The book closure runs from September 12 to September 30, 2026, and the company proposes a final dividend of ₹1.80 per share, an 18% payout on the ₹10 face value. Payment is subject to member approval.Business StandardLincoln Pharma jumps after Q1 PAT climbs 31% YoY to Rs 36 crLincoln Pharmaceuticals reported a 30.89% year-over-year increase in consolidated net profit to Rs 36.23 crore for Q1 FY27, driven by a 15.06% rise in net sales. The company is targeting Rs 1,000 crore in revenue over the next three years, supported by strong performance in key therapeutic segments and recent regulatory approvals in Canada, Australia, and the EU. Management emphasized its strategy to expand its global footprint to 90 countries while maintaining a debt-free balance sheet.Business StandardLincoln Pharmaceuticals consolidated net profit rises 30.89% in the June 2026 quarterLincoln Pharmaceuticals reported a 30.89% increase in consolidated net profit to Rs 36.23 crore for the quarter ended June 2026, compared to Rs 27.68 crore in the same period of the previous year. Sales revenue also grew by 15.06% to Rs 177.28 crore during this timeframe.ScanXLincoln Pharma Q1FY27 net profit up 31% YoY to ₹36.23 croreLincoln Pharmaceuticals reported a 31% year-over-year increase in Q1FY27 net profit to ₹36.23 crore, alongside a 19% rise in total income to ₹201.55 crore and significant expansion in EBITDA. The company aims to achieve annual revenue growth of 15-18% over the next three years, targeting ₹1,000 crore in revenue while expanding its export presence from over 60 to 90 countries. CRISIL Ratings reaffirmed the company's credit ratings on its bank facilities.Simply Wall StLincoln Pharmaceuticals (BSE:531633)Lincoln Pharmaceuticals Limited reported full year 2026 earnings with EPS of ₹43.88, up 6.7% year-on-year to net income of ₹878.9m on revenue of ₹7.04b, representing 13% growth in revenue from the prior year. The company has maintained consistent revenue growth averaging 8.8% annually over the past three years and declared a dividend of ₹1.80 per share (18%). However, investor sentiment has weakened following an 18% share price decline to ₹620, with the stock now trading at a P/E of 14.1x compared to an industry average of 29x.Financial ExpressLincoln Pharmaceuticals Share Price Today: Lincoln Pharmaceuticals Stock Price Live NSE/BSE, Lincoln Pharmaceuticals Share Price, Performance, Share Price Returns, HoldingsLincoln Pharmaceuticals shares declined by 5.3% to trade at ₹578.50, following the company's release of unaudited financial results for the quarter and nine months ended December 2025. The company reported consolidated net sales of Rs 166.32 crore and a net profit of Rs 28.60 crore for the most recent quarter, reflecting positive year-over-year growth.